21.0% Below Target

The consensus Wall Street price target for PACS is $50.67, representing 21.0% upside from the current price of $41.89. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

PACS has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $50.67 implies 21.0% upside from current levels.

With a forward P/E of 18.4075x, PACS trades at a relatively low valuation. The consensus target of $50.67 implies 21.0% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $52 for PACS, while the most conservative target is $48. The consensus of $50.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $64 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

PACS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month PACS stock forecast based on 8 Wall Street analysts shows a consensus price target of $50.67, with estimates ranging from $48 (bear case) to $52 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $49, with bear/bull scenarios of $31/$64.

Our quantitative valuation model calculates PACS's fair value at $49 (base case), with a bear case of $31 and bull case of $64. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.

PACS trades at a forward P/E ratio of 18.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are very optimistic on PACS, with a "Buy" consensus rating and $50.67 price target (21.0% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

PACS analyst price targets range from $48 to $52, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50.67 consensus represents the middle ground. Our model's $31-$64 range provides an independent fundamental perspective.